Bicara Therapeutics Inc. 4

CFO Hyep Ivan of Bicara Therapeutics Inc. exercised 12,500 stock options at $3.7898 and sold 28,000 shares of common stock on July 8, 2026 under a Rule 10b5-1 plan, ending with 129,855 shares owned directly.

On July 8, 2026, Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options for a total of 12,500 shares of common stock at an exercise price of $3.7898 per share and acquired these shares, then sold an aggregate 27,? (22,757 + 4,413 + 830 = 28,000) shares of common stock in three open-market transactions under a Rule 10b5-1 trading plan at weighted average prices of $28.602, $29.8246, and $30.3136, respectively. The option exercises appear to be routine vesting-related transactions from grants vesting in quarterly installments beginning April 5, 2023 and August 8, 2023, while the subsequent sales, executed across price ranges disclosed in the footnotes, reduced Ivan’s direct holdings to 129,855 shares of Bicara common stock. Based on the reported sale prices as a proxy for current market value, the option exercise cost was modest relative to the gross sale proceeds, and the remaining stake represents a sizable equity position for the CFO.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

4

Source Type

fda

Accession

0001470831-26-000700

Alert Tier

6